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Abstract
Objective: This study aimed to explore the role of  miR-126 in coronary artery disease (CAD) patients and the potential gene 
targets of  miR-126 in atherosclerosis.
Methodology: A total of  60 CAD patients and 25 healthy control subjects were recruited in this study. Among the 60 CAD 
patients, 18 cases were diagnosed of  stable angina pectoris (SAP), 20 were diagnosed of  unstable angina pectoris (UAP) and 22 
were diagnosed of  acute myocardial infarction (AMI). Plasma miR-126 levels from both groups of  participants were analyzed by 
real-time quantitative PCR. ELISA was used to measure plasma level of  placenta growth factor (PLGF).
Results: The results showed that the miR-126 expression was significantly down-regulated in the circulation of  CAD patients 
compared with control subjects (P<0.01). Plasma PLGF level was significantly upregulated in patients with unstable angina 
pectoris and acute myocardial infarction (AMI) compared with controls (both P<0.01) the miR-126 expression in AMI was 
significantly associated with PLGF.
Conclusion: miR-126 may serve as a novel biomarker for CAD.
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Atherosclerotic coronary artery disease (CAD) is one of  
the most important causes of  sudden cardiac death, ac-
counting for more than 80% of  the cases worldwide.1,2 
Despite recent advances in intervention and medication 
treatments, CAD is still considered to be a severe health 
threat with high morbidity and mortality worldwide.3 Fur-
ther development of  diagnosis and treatment based on 
novel molecular mechanisms are necessary for the further 
improvement to reduce the mortality of  CAD patients.
MicroRNAs (miRNAs) are small non-coding RNA 
molecules of  approximately 16-22 nucleotides.4 Recent 
researches have demonstrated that miRNAs serve as 
post-transcriptional regulators of  various genes expres-
sion through specific interaction with certain messenger 
RNAs (mRNAs) by inducing degradation or repressing 
translation of  the mRNAs.5,6 Recently, many studies have 
shown that miRNA expression could be a valuable sig-
nature for predicting the diagnosis and/or prognosis in 
patients of  cardiovascular diseases or cancer.7,8 In cardio-
vascular system, miRNAs were observed to be involved 
in heart and vascular development.9 Thus, it is reasonable 
to speculate a potential role of  miRNA in diagnosis, ther-
apeutic efficacy and prognosis evaluation in patients with 
CAD. In particular, aberrant expression of  miRNA-126 
was found in patients with atrial fibrillation, heart failure 
and CAD10,11, suggesting a regulatory role of  miRNA-126 
in cardiovascular system. Therefore, we first investigated 
the role of  miR-126 in atherosclerosis/CAD in this study. 
miR-126 as a positive regulator of  several vascular endo-
thelial growth factor (VEGF) family members including 
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PLGF. Then, we studied the plasma level of  placental 
growth factor (PLGF) as well as its correlation with miR-
126.
Methods
Characteristics of  patients
This study was approved by the Research Ethics Commit-
tee of  Affiliated Heping Hospital of  Changzhi Medical 
College, Changzhi, China. Written informed consent for 
the clinical study was obtained from all of  the patients. 
A total of  60 CAD patients diagnosed in our hospital 
between June 2015 and March 2016, were selected. 25 
normal healthy people were gathered from the medical 
examination center of  our hospital as the control group. 
Among the 60 CAD patients, 18 cases were diagnosed 
of  stable angina pectoris (SAP), 20 were diagnosed of  
unstable angina pectoris (UAP) and 22 were diagnosed 
of  acute myocardial infarction (AMI). Patients in CAD 
group were significantly older compared with control 
groups (p<0.05). Besides, CAD group had a significantly 
increased percentage of  diabetes mellitus, hypertension 
and smoking compared with controls (all p<0.05). High 
incidence of  both high and intermediate syntax scores 
were observed in CAD group. Diagnosis of  SAP and 
UAP were based on typical chest pain. Diagnosis of  AMI 
was based on either of  the several indexes listed below, 
including (1) ischemic symptoms; (2) increased levels of  
troponin and creatine kinase to >2 times the upper limit 
of  normal; (3) ST-segment abnormality; and (4) patholog-
ical Q wave12. Coronary angiography was used to confirm 
CAD and define the severity of  coronary artery lesions. 
Blood samples from each participant in both second and 
third cohorts were obtained immediately after admission, 
and plasma was stored at -80°C.
The Syntax score and angiographic analysis
Each coronary lesion with ≥ 50% diameter narrowing in 
vessels (≥ 1.5 mm) was calculated according to the base-
line diagnostic angiogram. The Syntax score algorithm 
was performed to calculate the overall Syntax score. Two 
experienced interventional cardiologists determined the 
Syntax score of  each patient blindly and independently. 
The final reported value was determined by the average 
value of  the two cardiologists.
Isolation of  total RNA and real-time polymerase 
chain reaction (RT-PCR) analysis
The plasma level of  miR-126 was quantified by RT-PCR. 
Total RNA was isolated by a RNAprep pure Blood Kit 
from Tiangen Biotechnology Co. Ltd. (Beijing, China), 
followed by a reverse transcription using a QuantScript 
RT Kit (Tiangen, Beijing, China) to synthesize the first 
strand of  complementary DNA (cDNA). cDNAs were 
then subjected to RT-PCR amplification using a 7500 
Fast RT-PCR System (Applied Biosystems, Foster City, 
CA, USA). TaqMan gene expression assay kit for miR-
126 (catalog number 000397) were obtained from Applied 
Biosystems (Foster City, CA, USA). The relative expres-
sion level of  miR-126 was determined by 2-∆∆CT method.
PLGF measurement
Level of  plasma PLGF was performed by high sensitivity 
indirect sandwich enzyme-linked immunosorbent assay 
(ELISA). Reading of  optical density was set at 450 nm 
and normalized to 570 nm according to the instruction 
by the manufacturer.
Statistical analysis
Data was reported as either means (standard deviation, 
SD). T test was used when comparing the difference 
between two groups and one-way analysis of  variance 
(ANOVA) was used when more than two groups were 
involved in the statistic analysis. The categorical variables 
were compared using χ2 test. Correlations between miR-
126 and PLGF as well as other biochemical parameters 
were performed with Pearson correlation analysis. Dif-




Patient characteristics are summarized in Table 1. Pa-
tients in CAD group were significantly older compared 
with control groups (p<0.05). Besides, CAD group had 
a significantly increased percentage of  diabetes mellitus, 
hypertension and smoking compared with controls (all 
p<0.05). High incidence of  both high and intermediate 
syntax scores were observed in CAD group. A sub-group 
analysis of  CAD patients showed significantly difference 
in population characteristics among SAP, UAP and AMI 
sub-groups (Table 1).
African Health Sciences Vol 17 Issue 2, June, 2017475




CAD (n=60) CAD subpopulation 
 
   SAP UAP AMI 
 
CAD: coronary artery disease patients; LDL-C: low density lipoprotein cholesterol; HDL-C: high density 
lipoprotein cholesterol. 
* p<0.05 between control and CAD groups 
[n, (%)] 11(44) 45(75) 18(30) 20(33.3) 22(36.7) 
Age (year) 52.8(13.3) 62.1(15.4) * 61.3(12.4) 63.2(11.8) 62.4(14.1) 
Diabetes 
mellitus (%) 
5(20) 7(11.7) * 2(3.33) 2(3.33) 3(5) 
Hypertension 
(%) 
7(28) 44(73.3) * 14(23.3) 15(25) 15(25) 
Current 
smoker  n (%) 




4.13(0.82) 4.06(0.98) 4.02(0.88) 4.08(0.82) 4.12(1.02) 
LDL-C 
(mmol/L) 
2.17(0.41) 2.46(0.81) 2.38(0.66) 2.47(0.58) 2.47(0.84) 
HDL-C 
(mmol/L) 
1.14(0.31) 1.16(0.33) 1.20(0.25) 1.17(0.34) 1.04(0.32) 
Triglyceride 
(mmol/L) 
1.92(0.55) 1.61(0.77) 1.72(0.69) 1.55(0.78) 1.60(0.72) 
Glucose 
(mmol/L) 
5.12(1.41) 6.77(2.49) 5.68(1.84) 6.86(2.38) 6.41(2.52) 
Ejection 
fraction (%) 
74.1(7.6) 73.1(6.5) 74.2(7.6) 70.6(6.2) 65.8(6.4) 
Syntax score           
 Low (0-22) 
[n, (%)] 




0(0) 3(5) 0(0) 1(1.67) 2(3.33) 
 High (33 or 
more) [n, (%)] 
0(0) 4(6.7) 0(0) 2(3.33) 2(3.33) 
MiR-126 was significantly down-regulated in CAD pa-
tients.
Circulating miR-126 level in CAD group (including SAP, 
UAP and AMI subgroups) was significantly lower than 
that in the control group (30 ± 12 in CAD group vs. 150 
± 32 in control group, p<0.01, Figure 1). Besides, cir-
culating miR-126 level was the lowest in AMI compared 
with SAP and UAP groups (Figure 1). 
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Figure 1. Circulating miR-126 levels in controls and CAD sub-groups. miR-126 was down regulated in CAD 
patients. AMI: acute myocardial infarction; CAD: coronary artery disease patients; SAP: stable angina pectoris; 
UAP: unstable angina pectoris.* p<0.05 vs. control. ^ p<0.05 vs. AMI. 
The syntax score was associated with plasma miR-126 level in this cohort (r = −0.468, P < 0.01, Figure 2).
 
Figure 2. Correlation between the Syntax score and plasma level of miR-126. 
Plasma PLGF level in CAD patients and its correla-
tion with miR-126
Plasma PLGF level was significantly higher in UAP and 
AMI compared with the control group (both p<0.01). 
However, patients with SAP showed no difference with 
the control group (p>0.05) (Figure 3). 
 
 
Figure 3. Plasma levels of PLGF in CAD patients and controls. * p<0.01 UAP vs. control and AMI vs. control. 
AMI: acute myocardial infarction; CAD: coronary artery disease patients; PLGF: placental growth factor; SAP: 
stable angina pectoris; UAP: unstable angina pectoris. 
African Health Sciences Vol 17 Issue 2, June, 2017477
Furthermore, miR-126 level was associated with plasma PLGF level in AMI group (r=0.455, p<0.05), but not in 
other sub-groups (Figure 4).
 
 
Figure 4. Correlation between PLGF and miR-126 in CAD patients. AMI: acute myocardial infarction; CAD: 
coronary artery disease patients; NS: no significant; PLGF: placental growth factor; SAP: stable angina pectoris; 
UAP: unstable angina pectoris. 
  Discussion
CAD is caused by atherosclerotic lesion which ultimate-
ly narrows the vessel lumen, causing the ischemic symp-
toms and cardiac dysfunction. CAD has been one of  the 
major health problems worldwide despite the advances 
in treatments.13,14 Thus, there is a crucial need to find 
new biomarkers and therapeutic targets for CAD to fur-
ther improve the prognosis of  these patients. Circulating 
miRNAs may be proposed by various clinical studies as 
prognostic biomarkers for CAD.15 For instance, one study 
showed that miR-133 and miR-208a were up-regulated in 
CAD patients compared to controls.16 Furthermore, The 
miRNA array analyses of  various human tissues have in-
dicated that miR-499 was produced almost exclusively in 
the heart and plasma concentration of  miR-499 may be 
a useful biomarker of  myocardial infarction in humans.17 
Moreover, accumulating evidence has suggested the use-
fulness of  circulating miRNAs as stable blood-based 
biomarkers for various diseases.18,19 Therefore, all those 
studies have pointed out that miRNA may be used as bio-
marker or even therapeutic targets for CAD.
MiRNA-126 is a short non-coding RNA that is derived 
from the (EGF Like Domain Multiple 7 (EGFL7) gene.20 
miR-126 is highly expressed in heart, liver, and lungs,21,22 
which was associated with activation of  the vascular en-
dothelial growth factor signaling pathway in the endothe-
lium. Those results indicated that miR-126 might have 
played a beneficial role in CAD.
Our results showed that miR-126 was down-regulated in 
patients with CAD. Furthermore, the severity of  CAD 
was associated with the expression level of  miR-126 in 
circulation. Therefore, our finding not only suggested a 
potential role of  miR-126 as a biomarker for CAD, but 
also indicated miR-126 as a useful marker for follow-up 
of  the CAD development in these patients. Moreover, 
we found that the decreased miR-126 in CAD was as-
sociated with increased plasma PLGF level and the two 
parameters inversely regulated with each other in AMI 
subgroups, which had more severe CAD and experienced 
more acute events. Although several studies have report-
ed the increased plasma PLGF levels in CAD patients, 
we firstly, reported the association between increased 
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PLGF level and unstable CAD including UAP and AMI 
in this study. More interestingly, we found a significant 
correlation between plasma miR-126 level and PLGF lev-
el, particularly in AMI. All these findings pointed to the 
possibility that unstable plaque in coronary artery could 
be featured by decreased miR-126 and increased PLGF. 
PLGF is an important protein in angiogenesis and has 
been proposed as a novel therapeutic target for angiogen-
ic disorders. In addition, angiogenesis is one of  the major 
mechanisms in atherosclerosis development. Therefore, 
this study unraveled a mechanistic possibility of  athero-
sclerosis development related to miR-126, and further 
studies are urgently needed.
Limitations
However, there are still several limitations in this study. 
First of  all, the sample should be increased to enhance 
the power of  the statistical analysis. Secondly, the find-
ings of  this study only suggested an association between 
miR-126 and CAD and/or PLGF. Mechanistic studies 
are needed to establish and causational among these three 
factors.
In this study, we found that circulating miR-126 level was 
significantly lower in patients with CAD and miR-126 
level correlated with severity of  CAD. Decreased miR-
126 level was associated with increased plasma PLGF lev-
els and a correlation existed between miR-126 and PLGF 
in AMI patients. Our data suggested miR-126 might be 
served as a potential marker for both CAD and severity 
of  CAD.
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